Gemcitabine-loaded cetuximab (CET) surface-modified poly(lactic) acid (PLA) NPs (CET-GEM/PLA NPs) targeting EGFR overexpressing A549 NSCLC cells determined a two-fold increase in fluorescent intensity compared to that of non-targeted NPs in the cancer cells and a greater level of cell apoptosis (early and late apoptosis ∼40%) [125]. This evidence concerns the gene EGFR and cancer.